Cancer therapy sensitizer

Details Cancer therapy sensitizer Cancer therapy sensitizer

2005-07-14

2009-12-29

Aeder, Sean E (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S006120, C435S007100, C424S130100, C424S193100

Reexamination Certificate

active

07638272

ABSTRACT:
The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.

REFERENCES:
patent: 5674743 (1997-10-01), Ulmer
patent: 5962320 (1999-10-01), Robinson
patent: 6187307 (2001-02-01), Cohen
patent: 6194205 (2001-02-01), Staege et al.
patent: 6239326 (2001-05-01), Howe
patent: 6316193 (2001-11-01), He et al.
patent: 6387664 (2002-05-01), Ikemoto
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6475784 (2002-11-01), Papkoff
patent: 2002/0169121 (2002-11-01), Ronai
patent: 2003/0082228 (2003-05-01), Flowers et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0229338 (2004-11-01), King
patent: WO 98/29138 (1998-07-01), None
patent: WO 00/72679 (2000-12-01), None
patent: WO 01/20989 (2001-03-01), None
patent: WO 01/25397 (2001-04-01), None
patent: WO 01/81631 (2001-11-01), None
patent: WO 02/02771 (2002-01-01), None
patent: WO 02/089772 (2002-11-01), None
patent: WO 2004/005883 (2004-01-01), None
patent: WO 2004/016758 (2004-02-01), None
patent: WO 2005/026357 (2005-03-01), None
Lankat-Buttgereit et al (FEBS Letters, Aug. 1988, 236:352-356).
Nair et al. (J. Immunol 2000 165(12): 6949-6955).
Hebbes et al. (Mol Immunol, 1989, 26(9):865-73).
Schwartz et al. (J. Immunol (1985) 135(4):2598-608).
Stites and Terr Eds (Basic and Clinical Immunology, Seventh Edition, 1991, Appleton and Lange, East Norwalk, Connecticut).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Chilenski, et al., Sparc is a key Schwanian-derived inhibitor controlling neuroblastoma tumor angionesis, Cancer Res., Dec. 15, 2002, vol. 62, pp. 7357-7363.
Yiu et al., SPARC (Secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells, Am. J. Pathol., Aug. 2001, vol. 159, No. 2, pp. 609-622.
International Search Report, Jul. 15, 2005, PCT/US04/00901.
Bellahcene et al., “Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer,”Am. J. Pathol. 146, 95-100 (Jan. 1995).
Bornstein, “Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1,”J. Cell Biol. 130,503-506 (1995).
Bradshaw et al., “SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury,”J. of Clinical Investigation, 107(9), 1049-1054 (May 2001).
Bradshaw et al., “SPARC-null mice exhibit increased adiposity without significant differences in overall body weight,”PNAS, 100(10), 6045-6050 (May 13, 2003).
Dhanesuan et al., “Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in gorwth inhibition,”Breast Cancer Research and Treatment, 75, 73-85 (2002).
Folkman, “Clinical applications of research on angiogenesis,”N. Engl. J. Med., 333(26), 1757-1763 (1995).
Georgiou et al., “Expression of correctly folded proteins inEscherichia coli,”Curr. Opn. in Biotechnology, 7, 190-197 (1996).
Gilbert et al., “SPARC gene expression is reduced in early diabetes-related kidney growth,”Kidney International, 48, 1216-1225 (1995).
Hasselaar et al., “SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells,”J. Cell. Biochem. 49, 272-283 (1992).
Hasselaar et al., “SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells,”J. of Biological Chemistry, 266(20), 13178-13184 (Jul. 15, 1991).
Hohenadl et al., “Two adjacent N-terminal glutamines of BM-40 (osteonectin, SPARC) act as amine acceptor sites in transglutaminaseC-catalyzed modification,”J. Biological Chemistry, 270(40), 23415-23420 (Oct. 6, 1995).
Jendraschak et al., “Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology,”Sem. Can. Biol. 7, 139-146 (1996).
Kim et al., “Expression of osteopontin and osteonectin in breast cancer,”J. Korean Med. Sci., 13, 652-657 (1998).
Lane et al., “SPARC is a source of copper-binding peptides that stimulate angiogenesis,”J. Cell. Biol., 125(4), 929-943 (May 1994).
Lane et al., “The biology of SPARC, a protein that modulates cell-matrix interactions,”FASEB J., 8, 163-173 (Feb. 1994).
Lane et al., “Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator imhibitor-1,”J. Biol. Chem. 267(23), 16736-16745 (Aug. 15, 1992).
Mason et al., “Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell ‘culture shock’ glycoprotein of Mr 43,000,”EMBO J., 5(7), 1465-1472 (1986).
Parikh et al., “Random mutagenesis by whole-plasmid PCR amplification,”Biotechniques, 24, 428-431 (Mar. 1998).
Pichler et al., “SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro,”Am. J. of Pathology, 148(4), 1153-1167 (Apr. 1996).
Porter et al, “Distribution of SPARC in Normal and neoplastic human tissue,”J. Histochemistry and Cytochemistry, 43(8), 791-800 (1995).
Qi et al, “L-RCA (ligation-rolling circle amplification): a general method for genotyping of single nucleotide polymorphisms (SNPs),”Nucleic Acids Research, 29(22) e116 (2001).
Raines et al., “The extracellular glycoprotein SPARC interacts with platelets-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors,”Proc. Natl. Acad. Sci. USA, 89, 1281-1285 (Feb. 1992).
Rempel et al., “SPARC: a potential diagnostic marker of invasive meningiomas,”Clinical Cancer Research, 5, 237-241 (Feb. 1999).
Sage et al., “Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin,”J. Biol. Chem., 266 (23), 14831-14834 (Aug. 15, 1991).
Sage et al., “Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence,”J. Cellular Biochemistry, 57, 127-140 (1995).
Sage et al., “Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis,”J. Biological Chemistry, 278(39) 37849-37857 (Sep. 26, 2003).
Swaroop et al., “Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q310q33,”Genomics, 2, 37-47 (1988).
Takahashi et al., “The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease,”Obesity Res., 9(7) 388-393 (Jul. 2001).
Werb, “ECM and cell surface proteolysis: regulating cellular ecology,”Cell, 91, 439-442 (Nov. 14, 1997).
Wolfsberg et al., “ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions,”J. Cell Biology, 131(2) 275-278 (Oct. 1995).
Yamanaka et al., “Analysis of the gene expression of SPARC and its prognostic value for bladder cancer,”J. Urology, 166, 2495-2499 (Dec. 2001).
Yan et al., “SPARC, a matricellular glycoprotein with important biological functions,”J. Histochem. Cytochem. 47 (12), 1495-1505 (1999).
Cree et al.,Curr. Opn. Invest. Drugs, 3 (4), 641-647 (2002).
Stein et al.,J. Natl. Cancer Inst., 88 (19), 1383-1392 (Oct. 2, 1996).
European Search Report for EP 04 70 2173 (Sep. 2, 2008).
Alliel et al.,Eur. J. Biochem, 21

Affiliated with

Also associated with

Rating

Cancer therapy sensitizer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer therapy sensitizer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer therapy sensitizer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4070900